Filing Flows › Biofrontera (BFRI) › Q4 2025
Biofrontera (BFRI) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 19, 2026
Biofrontera (BFRI) reported revenue of $17.1M for the fourth quarter 2025 (Q4 2025), +36% from a year earlier and +145% from the quarter before. Operating margin was 26.7%, net earnings $5.6M (33.0% of revenue).
Biofrontera, Q4 2025: revenue $17.1M (+36% year over year), operating margin 26.7%, net earnings $5.6M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.1M | +145% | +36% |
| Operating profit | $4.6M | — | — |
| Net earnings | $5.6M | — | — |
| Operating cash flow | −$2.4M | — | — |
What changed
Revenue was $17.1M in Q4 2025, up 36% year over year and up 145% from the previous quarter.
Operating profit was $4.6M, a 26.7% margin (up 40.3 points year over year). Total costs fell 12% while revenue rose 36%. Net earnings were $5.6M. The effective tax rate was 0.0%.
Operating cash flow was −$2.4M. Non-cash charges added back $36K of depreciation and $289K of share-based compensation. Working capital and other items used $8.3M. Capital expenditures of −$1K exceeded it, leaving free cash flow of −$2.4M.
Questions
What was Biofrontera's revenue in the fourth quarter 2025?
Biofrontera (BFRI) reported revenue of $17.1M for the fourth quarter 2025 (Q4 2025), +36% from a year earlier and +145% from the quarter before.
Was Biofrontera profitable in the fourth quarter 2025?
Operating profit was $4.6M (26.7% of revenue) and net earnings $5.6M.
Source: Biofrontera 10-K on SEC EDGAR.